Brand names: Neulasta®
Pegfilgrastim (E. coli) Solution for injection
What is this medicine?
PEGFILGRASTIM (peg fil GRA stim) helps the body make more white blood cells. It is used to prevent infection in people with low amounts of white blood cells following cancer treatment.
This medicine may be used for other purposes; ask your health care provider or pharmacist if you have questions.
What should I tell my health care provider before I take this medicine?
They need to know if you have any of these conditions:
•sickle cell disease
•an unusual or allergic reaction to pegfilgrastim, filgrastim, E.coli protein, other medicines, foods, dyes, or preservatives
•pregnant or trying to get pregnant
•breast-feeding
How should I use this medicine?
This medicine is for injection under the skin. It is usually given by a health care professional in a hospital or clinic setting.
If you get this medicine at home, you will be taught how to prepare and give this medicine. Do not shake this medicine. Use exactly as directed. Take your medicine at regular intervals. Do not take your medicine more often than directed.
It is important that you put your used needles and syringes in a special sharps container. Do not put them in a trash can. If you do not have a sharps container, call your pharmacist or healthcare provider to get one.
Talk to your pediatrician regarding the use of this medicine in children. While this drug may be prescribed for children who weigh more than 45 kg for selected conditions, precautions do apply
Overdosage: If you think you have taken too much of this medicine contact a poison control center or emergency room at once.
NOTE: This medicine is only for you. Do not share this medicine with others.
What may interact with this medicine?
•lithium
•medicines for growth therapy
This list may not describe all possible interactions. Give your health care provider a list of all the medicines, herbs, non-prescription drugs, or dietary supplements you use. Also tell them if you smoke, drink alcohol, or use illegal drugs. Some items may interact with your medicine.
What should I watch for while using this medicine?
Visit your doctor for regular check ups. You will need important blood work done while you are taking this medicine.
What side effects may I notice from receiving this medicine?
Side effects that you should report to your doctor or health care professional as soon as possible:
•allergic reactions like skin rash, itching or hives, swelling of the face, lips, or tongue
•breathing problems
•fever
•pain, redness, or swelling where injected
•shoulder pain
•stomach or side pain
Side effects that usually do not require medical attention (report to your doctor or health care professional if they continue or are bothersome):
•aches, pains
•headache
•loss of appetite
•nausea, vomiting
•unusually tired
This list may not describe all possible side effects. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
Where should I keep my medicine?
Keep out of the reach of children.
Store in a refrigerator between 2 and 8 degrees C (36 and 46 degrees F). Do not freeze. Keep in carton to protect from light. Throw away this medicine if it is left out of the refrigerator for more than 48 hours. Throw away any unused medicine after the expiration date.
Last updated: 2/28/2005 11:16:00 AM
Important Disclaimer: The drug information provided here is for educational purposes only. It is intended to supplement, not substitute for, the diagnosis, treatment and advice of a medical professional. This drug information does not cover all possible uses, precautions, side effects and interactions. It should not be construed to indicate that this or any drug is safe for you. Consult your medical professional for guidance before using any prescription or over the counter drugs.
| pegaptanib sodium, pastille, paste | |
| peginterferon alfa, pegvisomant, pemetrexed |
| Systematic (IUPAC) name | |
|---|---|
| N-(3-Hydroxypropyl)Methionylcolony-stimulating Factor (human), 1-Ether with .Alpha.-Methyl-.Omega.-Hydroxypoly(Oxyethylene) | |
| Clinical data | |
| Trade names | Neulasta |
| AHFS/Drugs.com | monograph |
| MedlinePlus | a607058 |
| Pregnancy cat. | C (US) |
| Legal status | ℞-only (US) |
| Pharmacokinetic data | |
| Half-life | 15-80 hrs |
| Identifiers | |
| CAS number | 208265-92-3 |
| ATC code | L03AA13 |
| DrugBank | DB00019 |
| UNII | 3A58010674 |
| KEGG | D06889 |
| ChEMBL | CHEMBL1201568 |
| Chemical data | |
| Formula | C845H1343N223O243S9 + PEG |
| Mol. mass | 39000 g/mol |
| |
|
Pegfilgrastim is a PEGylated form of the recombinant human granulocyte colony-stimulating factor (GCSF) analog filgrastim. It serves to stimulate the level of white blood cells (neutrophils).[1]
Amgen manufactures pegfilgrastim under the brand name Neulasta, and Roche under the name Neulastim. The drug is prepared by coupling a 20 kDa polyethylene glycol (PEG) molecule to the N-terminus of the filgrastim protein. Pegfilgrastim has a human half-life of 15 to 80 hours, much longer than the parent filgrastim (3–4 hours).[2][3]
Pegfilgrastim treatment can be used to stimulate the bone marrow to produce more neutrophils to fight infection in patients undergoing chemotherapy.[3]
|
|||||||||||||||||||||||||||||
| This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |
This entry is from Wikipedia, the leading user-contributed encyclopedia. It may not have been reviewed by professional editors (see full disclaimer)